Sepsis is a clinical syndrome with high mortality and morbidity rates. In sepsis, the abrupt release of cytokines by the innate immune system may cause multiorgan failure, leading to septic shock and associated complications. In the presence of a number of systemic disorders, such as sepsis, infections, diabetes, and systemic lupus erythematosus (SLE), cardiorenal syndrome (CRS) type 5 is defined by concomitant cardiac and renal dysfunctions Thus, our study suggests that certain mRNAs and unexplored pathways may pave a way to unravel critical therapeutic targets in three debilitating and interrelated illnesses, namely, sepsis, SLE, and CRS. Sepsis, SLE, and CRS are closely interrelated complex diseases likely sharing an overlapping pathogenesis caused by erroneous gene network activities. We sought to identify the shared gene networks and the key genes for sepsis, SLE, and CRS by completing an integrative analysis. Initially, 868 DEGs were identified in 16 GSE datasets. Based on degree centrality, 27 hub genes were revealed. The gProfiler webtool was used to perform functional annotations and enriched molecular pathway analyses. Finally, core hub genes (EGR1, MMP9, and CD44) were validated using RT-PCR analysis. Our comprehensive multiplex network approach to hub gene discovery is effective, as evidenced by the findings. This work provides a novel research path for a new research direction in multi-omics biological data analysis.

The members of the Liliaceae family are considered an excellent source of biologically active compounds. However, work on antimicrobial potential and characterization of the bioactive fractions of the Lilium philadelphicum flower is limited and needs to be explored. The present study reports the antimicrobial potential of the bioactive fraction extracted from the flower of L. philadelphicum (red lily) and partial characterization of the bioactive compound(s). The antimicrobial activity was tested against nine different Gram-positive and Gram-negative bacterial strains. The minimum inhibitory concentration (MIC) values of methanolic extract of the L. philadelphicum flower against Acinetobacter bouvetii, Achromobacter xylosoxidans, Bacillus subtilis MTCC 121, Candida albicans MTCC 183, Klebsiella pneumoniae MTCC 3384, and Salmonella typhi MTCC 537 were 25, 50, 12.5, 50, 100, and 50 μg/mL, respectively. The phytochemical analysis of the extract revealed the presence of phenols, flavonoids, tannins, terpenoids, glycosides, coumarins, and quinones. The cytotoxicity of the partially purified compound against the HepG2 cell line using MTT assay demonstrated up to 90% cell viability with a bioactive compound concentration of 50 μg/mL. However, the increase in the bioactive compound’s concentration up to 1000 μg/mL resulted in nearly 80% cell viability. This minor decline in cell viability suggests the importance and suitability of the bioactive compound for therapeutic applications. Spectroscopic studies of the bioactive compound by UV-visible spectroscopy, FT-infrared spectroscopy, gas chromatography-mass spectrometry (GC-MS), as well as phytochemical analysis, suggested the presence of a terpenoid moiety, which may be responsible for the antimicrobial property of the L. philadelphicum flower.